Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

NCT ID: NCT00623467

Last Updated: 2014-02-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

343 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Gadavist. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI will be compared to the results of images taken without Gadavist.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Issues on safety will be addressed in Adverse Events section.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Nervous System Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gadobutrol (Gadavist, BAY86-4875)

Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.

Group Type EXPERIMENTAL

Gadobutrol (Gadavist, Gadovist, BAY86-4875)

Intervention Type DRUG

Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gadobutrol (Gadavist, Gadovist, BAY86-4875)

Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients referred for contrast enhanced MRI of the CNS based on symptoms or previous procedures.

Exclusion Criteria

* Patients with acute renal insufficiency
* Patients with severe renal disease
* Patients with any contraindication to magnetic resonance imaging.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HOPE Research Institute, LLC

Phoenix, Arizona, United States

Site Status

Scottsdale Medical Imaging, Ltd.

Scottsdale, Arizona, United States

Site Status

Radiology Ltd.

Tucson, Arizona, United States

Site Status

Landmark Imaging Medical Group

Los Angeles, California, United States

Site Status

Cedars- Sinai Medical Center

Los Angeles, California, United States

Site Status

Sharp & Children's MRI Center

San Diego, California, United States

Site Status

University of Florida - Jacksonville

Jacksonville, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

River Birch Research Alliance, LLC

Blue Ridge, Georgia, United States

Site Status

Eisenhower Army Medical Center

Fort Gordon, Georgia, United States

Site Status

University of Michigan Health System

Ann Arbor, Michigan, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Bio-Magnetic Resonance, Inc.

Madison Heights, Michigan, United States

Site Status

Maimonides Medical Center

Brooklyn, New York, United States

Site Status

Mount Sinai Medical Center

New York, New York, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

Wake Forest University School of Medicine

Winston-Salem, North Carolina, United States

Site Status

Hahnemann University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Investigaciones Médicas

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Milbet Diagnostico por Imagenes

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Hospital Italiano Buenos Aires

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Centro de Diagnóstico Dr. Enrique Rossi

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Site Status

Zhongda Hosp. affiliated of Southeast Univ.

Nanjing, Jiangsu, China

Site Status

The 1st Affiliated Hosp of the 4th Military Med Uni

Xi'an, Shaanxi, China

Site Status

Chinese PLA General Hosp.

Beijing, , China

Site Status

Affiliated Ruijin Hosp. Shanghai Jiaotong Univ. Med School

Shanghai, , China

Site Status

Fudan University Huashan Hospital

Shanghai, , China

Site Status

Fundación Instituto de Alta tecnología médica de Antioquia

Medellín, Antioquia, Colombia

Site Status

Fundación Santa Fe de Bogotá - Hospital Universitario

Bogotá, Cundinamarca, Colombia

Site Status

The Catholic University of Korea Seoul St. Mary's Hospital

Seoul, Korea, South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University College of Medicine

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina China Colombia South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

91682

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gadopiclenol vs Gadoxetate MRI for Liver Lesions
NCT06596616 ENROLLING_BY_INVITATION